Guardant Health beats Q1 revenue estimates as Shield test demand lifts 2026 outlook

Guardant Health (NASDAQ: GH) reported first-quarter 2026 revenue of $301.7 million, up 48.3% from a year earlier and above Wall Street expectations, driven by higher demand across oncology, biopharma and colorectal cancer screening. The diagnostics company posted a GAAP loss of $0.85 per share, 5.9% wider than analysts’ consensus estimate. Management said adoption of its Shield colorectal cancer test accelerated, while oncology testing volumes and recent product updates also supported growth. Guardant surpassed $1 billion in trailing 12-month revenue for the first time. Guardant guided for full-year 2026 revenue of $1.31 billion at the midpoint, 3.1% above analyst estimates. The company said it plans to reinvest incremental screening gross profit into commercial expansion while pursuing new product launches, biopharma partnerships and reimbursement opportunities tied to oncology, minimal residual disease and multi-cancer detection. Shares recently traded at $92.09, little changed from $92.26 before the earnings release.